BUND FINANCE

BUND FINANCE › Stocks › ONC

BeOne Medicines AG (ONC)

NASDAQ · Stock price, chart and technical analysis

US$403.60-9.66 (-2.34%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$413.26
OpenUS$407.20
Day rangeUS$401.89 – US$409.66
52-week rangeUS$253.95 – US$424.73
Market capUS$43.13B
Volume243,136
50-day averageUS$371.47
200-day averageUS$328.49
Beta0.52

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$1.2BUS$1.4BUS$2.5BUS$3.8BUS$5.3B
Net income−US$1.5B−US$2.0B−US$881.7M−US$644.8MUS$286.9M
EPS (diluted)-15.21-19.37-8.45-6.122.53
Gross margin86.0%79.8%84.6%84.4%87.5%
Operating margin-122.3%-126.4%-49.1%-14.9%8.4%
Net margin-123.9%-141.5%-35.9%-16.9%5.4%
Free cash flow−US$1.6B−US$2.0B−US$1.8B−US$669.8MUS$941.7M
Total debtUS$694.6MUS$596.7MUS$930.2MUS$1.1BUS$2.0B
CashUS$4.4BUS$3.9BUS$3.2BUS$2.6BUS$4.5B

Compound annual growth: revenue 46.0% · net income — (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E6.5x115.5x27.1x
EV / EBITDA27.0x49.6x16.5x
Operating margin17.8%—3.6%
Net margin13.9%—-0.0%
Debt / equity0.70—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About BeOne Medicines AG

SectorHealthcare
IndustryBiotechnology
CountryCH
CEOJohn V. Oyler
Employees12,000
IPO date2016-02-03

BeOne Medicines AG, an oncology-focused enterprise headquartered in Basel, Switzerland, was established in 2010. This company is actively involved in the exploration and advancement of a diverse range of therapeutic solutions for cancer patients across key global regions, including the United States, China, Europe, and other international markets. Its current commercial portfolio features several significant treatments: BRUKINSA: A small molecule designed to inhibit Bruton's Tyrosine Kinase (BTK), indicated for various blood cancers. TEVIMBRA: An anti-PD-1 antibody immunotherapy utilized in the treatment of both solid tumors and blood cancers. PARTRUVIX: A selective small molecule inhibitor …

beonemedicines.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice